Abstract
The 1-deoxysphingolipids (1-deoxySLs) are formed by an alternate substrate usage of the enzyme, serine-palmitoyltransferase, and are devoid of the C1-OH-group present in canonical sphingolipids. Pathologically elevated 1-deoxySL levels are associated with the rare inherited neuropathy, HSAN1, and diabetes type 2 and might contribute to β cell failure and the diabetic sensory neuropathy. In analogy to canonical sphingolipids, it was assumed that 1-deoxySLs also bear a (4E) double bond, which is normally introduced by sphingolipid delta(4)-desaturase 1. This, however, was never confirmed. We therefore supplemented HEK293 cells with isotope-labeled D3-1-deoxysphinganine and compared the downstream formed D3-1-deoxysphingosine (1-deoxySO) to a commercial synthetic SPH m18:1(4E)(3OH) standard. Both compounds showed the same m/z, but differed in their RPLC retention time and atmospheric pressure chemical ionization in-source fragmentation, suggesting that the two compounds are structural isomers. Using dimethyl disulfide derivatization followed by MS2 as well as differential-mobility spectrometry combined with ozone-induced dissociation MS, we identified the carbon-carbon double bond in native 1-deoxySO to be located at the (Δ14) position. Comparing the chromatographic behavior of native 1-deoxySO to chemically synthesized SPH m18:1(14Z) and (14E) stereoisomers assigned the native compound to be SPH m18:1(14Z). This indicates that 1-deoxySLs are metabolized differently than canonical sphingolipids.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Journal of Lipid Research |
| Jahrgang | 57 |
| Ausgabenummer | 7 |
| Seiten (von - bis) | 1194-1203 |
| Seitenumfang | 10 |
| ISSN | 0022-2275 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.07.2016 |
Fördermittel
This work was supported by the 7th Framework Program of the European Commission ("RESOLVE", project number 305707), the Swiss National Science Foundation (SNF) (Project 31003A-153390/1), the Hurka Foundation, the Novartis Foundation, the Rare Disease Initiative Zurich ("radiz", Clinical Research Priority Program for Rare Diseases, University of Zurich) (R.S., A.O., A.v.E, T.H.); and project funding through the Australian Research Council via the Discovery and Linkage programs (DP150101715 and LP110200648; the latter is an industry partnership with SCIEX, Ontario, Canada) (S.J.B.).
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Elucidating the chemical structure of native 1-deoxysphingosine“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver